Unfortunately, reports of AFFs with bisphosphonate treatment "have contributed to a crisis in osteoporosis treatment," with use declining by half from 2008 to 2012, the researchers wrote.

If bone density at the hip is normal or only mildly reduced, ... DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010;95:1555-1565. Crossref. PubMed. Web of Science ...

Osteoporosis, a disease characterized by reduced bone mass and increased skeletal fragility, affects 10 million Americans; another 34 million are at risk for it. Bisphosphonates are widely ...

Bisphosphonates are the mainstay of osteoporosis therapy. Extensive clinical evaluation supports their utility in stemming progression of the disease and in reducing fracture risk. In the course ...

Although the update to the 2017 ACP guideline on drug treatment for osteoporosis now advises bisphosphonates as initial therapy, an editorialist admits the decision to use them is not always easy.

In spite of the known or suspected risks, doctors say the benefits of bisphosphonate drugs — reducing fractures in people with osteoporosis — far outweigh the low risk of the potential adverse ...

The reputation of bisphosphonates, the most widely prescribed osteoporosis drugs on the market, has taken a beating lately. Last month, a study in the New England Journal of Medicine by the U.S ...

A recent study aimed to determine the clinical and laboratory parameters associated with increased fracture risk in patients on holidays from taking bisphosphonates (BP) for osteoporosis.

The incidence of CVD during the 1-year follow-up period was 12.3 vs 11.4 per 100 person-years among the romosozumab vs bisphosphonate groups, respectively.

On top of that, 200 postmenopausal women with osteoporosis would need 12.1 months (95% CI 6.4-17.8 months) of bisphosphonate therapy to avoid one clinical vertebral fracture at an ARR of 0.005.

who have been assessed as being at higher risk of osteoporotic fragility fracture using the methods recommended in NICE's guideline on osteoporosis (recommendations 1.3 to 1.12) and NICE's quality ...